GenMark Diagnostics (GNMK) 10-Q 4 Aug 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Jul. 30, 2020
Document and Entity Information [Abstract]
Entity Registrant Name	GenMark Diagnostics, Inc.
Entity Central Index Key	0001487371
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Entity Current Reporting Status	Yes
Entity Shell Company	false
Amendment Flag	false
Entity Common Stock, Shares Outstanding		71,071,323
Entity File Number	001-34753
Entity Address, Address Line One	5964 La Place Court
Entity Address, City or Town	Carlsbad
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92008
City Area Code	760
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	GNMK
Security Exchange Name	NASDAQ
Local Phone Number	448-4300
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes
Entity Tax Identification Number	27-2053069

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019
Current Assets:
Cash and cash equivalents	$ 82,421,000	$ 44,360,000	$ 23,733,000
Short-term marketable securities	50,374,000	9,100,000
Accounts receivable, net of allowances of $1,132 and $376, respectively	17,867,000	16,759,000
Inventories, net	14,927,000	11,301,000
Prepaid expenses and other current assets	1,823,000	1,877,000
Total current assets	167,412,000	83,397,000
Property and equipment, net	19,420,000	20,419,000
Intangible assets, net	1,137,000	1,432,000
Restricted cash	1,646,000	758,000	758,000
Other long-term assets	1,026,000	825,000
Total assets	195,013,000	111,473,000
Current liabilities:
Accounts payable	15,421,000	12,249,000
Accrued compensation	8,609,000	7,493,000
Operating Lease, Liability, Current	1,870,000	1,842,000
Other current liabilities	3,245,000	2,732,000
Total current liabilities	29,145,000	24,316,000
Long-term debt	70,189,000	69,145,000
Operating Lease, Liability, Noncurrent	5,217,000	5,796,000
Other noncurrent liabilities	285,000	53,000
Total liabilities	104,836,000	99,310,000
Stockholders' equity:
Preferred stock, $0.0001 par value; 5,000 authorized, none issued	0	0
Common stock, $0.0001 par value; 100,000 authorized; 70,693 and 60,255 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively	7,000	6,000
Additional paid-in capital	615,995,000	526,294,000
Accumulated deficit	(525,925,000)	(514,233,000)
Accumulated other comprehensive income	100,000	96,000
Total stockholders’ equity	90,177,000	12,163,000	14,781,000
Total liabilities and stockholders’ equity	195,013,000	111,473,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	84,067,000	45,118,000	$ 24,491,000
Operating Lease, Right-of-Use Asset	$ 4,372,000	$ 4,642,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Accounts receivable - net of allowance	$ 107	$ 376
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, authorized	100,000,000	100,000,000
Common stock, issued	70,693,000	60,255,000
Common stock, outstanding	70,693,000	60,255,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 39,460	$ 18,071	$ 77,813	$ 39,282
Revenue:
Other revenue	626	303	1,015	625
Total revenue	40,086	18,374	78,828	39,907
Cost of revenue	24,235	11,801	46,825	27,471
Gross profit	15,851	6,573	32,003	12,436
Operating expenses:
Sales and marketing	6,285	5,803	12,425	11,712
General and administrative	4,622	4,931	13,560	9,452
Research and development	7,637	7,749	13,716	14,092
Total operating expenses	18,544	18,483	39,701	35,256
Loss from operations	(2,693)	(11,910)	(7,698)	(22,820)
Other income (expense):
Interest income	109	179	241	312
Interest expense	(2,037)	(1,528)	(4,128)	(2,804)
Other expense	0	(4)	(29)	(15)
Total other expense	(1,928)	(1,353)	(3,916)	(2,507)
Loss before provision for income taxes	(4,621)	(13,263)	(11,614)	(25,327)
Income tax expense	63	45	78	61
Net Income (Loss) Attributable to Parent	$ (4,684)	$ (13,308)	$ (11,692)	$ (25,388)
Net loss per share, basic and diluted	$ (0.07)	$ (0.23)	$ (0.18)	$ (0.45)
Weighted average number of shares outstanding, basic and diluted	66,528	57,171	63,597	56,878
Other comprehensive loss:
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	$ 10	$ 15	$ (29)	$ 9
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax	29	6	33	8
Other Comprehensive Income (Loss), Net of Tax	39	21	4	17
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$ (4,645)	$ (13,287)	$ (11,688)	$ (25,371)

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Operating activities:
Net loss	$ 11,692,000	$ 25,388,000
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,479,000	3,616,000
Net amortization (accretion) of premiums/discounts on investments	34,000	(98,000)
Amortization of deferred debt issuance costs	1,145,000	816,000
Stock-based compensation	8,048,000	5,711,000
Provision for bad debt	766,000	46,000
Non-cash inventory adjustments	850,000	897,000
Other non-cash adjustments	(49,000)	125,000
Changes in operating assets and liabilities:
Accounts receivable	(1,866,000)	4,720,000
Inventories	(4,960,000)	(1,387,000)
Prepaid expenses and other assets	(382,000)	(784,000)
Accounts payable	3,598,000	(1,143,000)
Accrued compensation	624,000	(2,490,000)
Other current and non-current liabilities	790,000	(257,000)
Net cash provided by (used in) operating activities	385,000	(15,616,000)
Investing activities:
Purchases of property and equipment	(1,703,000)	(467,000)
Purchases of marketable securities	(52,123,000)	(19,440,000)
Maturities of marketable securities	9,655,000	10,800,000
Net cash used in investing activities	(42,978,000)	(9,107,000)
Financing activities:
Proceeds from issuance of common stock, net of offering costs	78,078,000	464,000
Principal repayment of borrowings	(33,000)	(35,140,000)
Proceeds from borrowings	0	50,000,000
Payments associated with debt issuance	(100,000)	(3,588,000)
Proceeds from stock option exercises	(3,575,000)	(432,000)
Net cash provided by financing activities	81,520,000	12,168,000
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	22,000	2,000
Net increase (decrease) in cash, cash equivalents, and restricted cash	38,949,000	(12,553,000)
Cash, cash equivalents, and restricted cash at beginning of year	45,118,000	37,044,000
Cash, cash equivalents, and restricted cash at end of period	84,067,000	24,491,000
Non-cash investing and financing activities:
Transfer of systems to property and equipment from inventory	483,000	822,000
Property and equipment included in accounts payable	807,000	18,000
Supplemental cash flow information:
Cash paid for income taxes, net	48,000	104,000
Cash paid for interest	3,080,000	1,837,000
Proceeds from Sale of Available-for-sale Securities	$ 1,193,000	$ 0

Statement of Stockholders' Equi

Statement of Stockholders' Equity Statement - USD ($) $ in Thousands	Total	Additional Paid-in Capital [Member]	Common Stock [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]
Shares, Outstanding			56,240,000
Stockholders' Equity Attributable to Parent	$ 33,547	$ 500,344	$ 6	$ 80	$ (466,883)
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	5,711	5,711
Stock Issued During Period, Shares, Employee Stock Purchase Plans			105,000
Stock Issued During Period, Value, Employee Stock Purchase Plan	464	464
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures			71,000
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	430	430
Net Income (Loss) Attributable to Parent	(25,388)				(25,388)
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures			1,014,000
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax	8			8
Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease)	9			9
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax	8
Shares, Outstanding			57,026,000
Stockholders' Equity Attributable to Parent	24,437	503,318	$ 6	76	(478,963)
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	$ 3,167	3,167
Stock Issued During Period, Shares, Employee Stock Purchase Plans	105,000
Stock Issued During Period, Value, Employee Stock Purchase Plan	$ 464	464
Net Income (Loss) Attributable to Parent	(13,308)				(13,308)
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures			299,000
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax	6			6
Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease)	15			15
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax	6
Shares, Outstanding			57,430,000
Stockholders' Equity Attributable to Parent	14,781	506,949	$ 6	97	(492,271)
Shares, Outstanding			60,255,000
Stockholders' Equity Attributable to Parent	12,163	526,294	$ 6	96	(514,233)
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	8,048	8,048
Stock Issued During Period, Shares, Employee Stock Purchase Plans			103,000
Stock Issued During Period, Value, Employee Stock Purchase Plan	488	488
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures			659,000
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	3,575	3,575
Net Income (Loss) Attributable to Parent	$ (11,692)				(11,692)
Stock Issued During Period, Shares, New Issues (in shares)	363,120		8,705,000
Stock Issued During Period, Value, New Issues	$ 77,591	77,590	$ 1
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent	33			33
Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease)	(29)			(29)
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax	33
Stock Issued During Period, Shares, Restricted Stock Award, Gross			971,000
Shares, Outstanding			61,333,000
Stockholders' Equity Attributable to Parent	13,003	534,177	$ 6	61	(521,241)
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	$ 2,428	2,428
Stock Issued During Period, Shares, Employee Stock Purchase Plans	103,000
Stock Issued During Period, Value, Employee Stock Purchase Plan	$ 488	488
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures			638,000
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	3,472	3,472
Net Income (Loss) Attributable to Parent	(4,684)				(4,684)
Stock Issued During Period, Shares, New Issues (in shares)			8,342,000
Stock Issued During Period, Value, New Issues	75,431	75,430	$ 1
Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease)	10			10
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax	29			29
Stock Issued During Period, Shares, Restricted Stock Award, Gross			277,000
Shares, Outstanding			70,693,000
Stockholders' Equity Attributable to Parent	$ 90,177	$ 615,995	$ 7	$ 100	$ (525,925)

Organization and Basis of Prese

Organization and Basis of Presentation (Notes)	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation GenMark Diagnostics, Inc., the Company or GenMark, was formed by Osmetech plc as a Delaware corporation in February 2010, and had no operations prior to its initial public offering, which was completed in June 2010. The Company is a provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP, and applicable regulations of the U.S. Securities and Exchange Commission, or the SEC, and should be read in conjunction with the audited financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed with the SEC on March 2, 2020. These unaudited condensed consolidated financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. These adjustments are of a normal, recurring nature. Interim period operating results may not be indicative of the operating results for the full year or any future period. In June 2020, the Company made a policy election to reclassify freight revenue from product revenue to other revenue. The Company reclassified freight revenue of $149,000 and $309,000 for the three and six months ended June 30, 2019 from product revenue to other revenue to conform with the current year presentation. The reclassification had no impact to total revenue for the periods presented. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The Company has experienced net losses and negative cash flows from operating activities since its inception and had an accumulated deficit of $525,925,000 as of June 30, 2020. The Company's ability to transition to profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure through expanding its product offerings and consequently increasing its product revenues. As of June 30, 2020, the Company had available cash, cash equivalents, and marketable securities of $132,795,000 and working capital of $138,267,000 available to fund future operations. The Company has prepared cash flow forecasts which indicate, based on the Company's current cash resources available and working capital, that the Company will have sufficient resources to fund its operations for at least one year after the date the financial statements are issued. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes thereto. The Company’s significant estimates included in the preparation of the financial statements are related to accounts receivable, inventories, property and equipment, leases, intangible assets, employee-related compensation accruals, warranty liabilities, tax valuation accounts, and stock-based compensation. Actual results could differ from those estimates. Segment Information The Company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales and support of instruments and molecular tests based on its proprietary eSensor ® detection technology. Substantially all of the Company’s operations and assets are in the United States. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or the FASB, or other standard setting bodies that the Company adopts as of the specified effective date. In February 2016, the FASB issued ASU 2016-02, Leases, which outlines a comprehensive lease accounting model and supersedes the prior lease guidance. The new guidance requires lessees to recognize lease liabilities and corresponding right-of-use, or ROU, assets for all leases with lease terms of greater than 12 months. The guidance also changes the definition of a lease and expands the disclosure requirements of lease arrangements. The new guidance must be adopted using the modified retrospective approach and is effective for annual periods beginning after December 15, 2018. The Company adopted the new standard in the first quarter of 2019 using the package of transition practical expedients. The Company recognized non-current ROU assets of $5,097,000 and current and non-current lease liabilities of $1,780,000 and $6,832,000, respectively, upon adoption. Deferred rent is now presented as an offset to the Company's non-current operating lease ROU assets. The new lease standard did not have a material impact on the Company's unaudited condensed consolidated statements of operations, cash flows, or stockholders' equity. In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments , which introduced a new methodology for recognizing credit losses on financial instruments. The new standard requires entities to measure financial instruments at their amortized cost basis, net of an allowance for credit losses. The allowance for credit losses must reflect an entity's current estimate of all expected credit losses. The new guidance also requires entities to present credit losses on debt securities accounted for under the available-for-sale method as an allowance rather than a write down. The Company adopted the new standard in the first quarter of 2020. The adoption of ASU 2016-13 did not have a material impact on the Company’s unaudited condensed consolidated financial statements for the three and six months ended June 30, 2020. Revenue The Company recognizes revenue from operations through the sale of products and other services. Product revenue comprises the sale of diagnostic tests and instruments. Other revenue primarily consists of freight revenue and revenue from extended service agreements. Revenue is recognized when control of products and services is transferred to the customer in an amount that reflects the consideration that the Company expects to receive from the customer in exchange for those products and services. This process involves identifying the contract with the customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control. Revenue from product sales is recognized generally upon shipment to the end customer, which is when control of the product is deemed to be transferred. Invoicing typically occurs upon shipment and the term between invoicing and when payment is due is not significant. Revenue from instrument services is recognized as the services are rendered, typically evenly over the contract term. Revenue is recorded net of discounts and sales taxes collected on behalf of governmental authorities. Employee sales commissions are recorded as sales and marketing expense when incurred or amortized over the estimated contract term when resulting from new contract acquisition efforts. The Company allocates contract price to each performance obligation in proportion to its stand-alone selling price. The stand-alone selling price is determined by the Company's best estimate of stand-alone selling price using average selling prices over a rolling 12-month period along with a specific assessment of any unique circumstances of the contract. For those products for which there is limited sales history, the Company makes price determinations based on similar product sales data. The following table represents disaggregated revenue by source (in thousands): Three Months Ended Six Months Ended 2020 2019 2020 2019 Revenue Source: ePlex product revenue $ 35,216 $ 11,935 $ 69,185 $ 27,466 XT-8 product revenue 4,244 6,136 8,628 11,816 Total product revenue 39,460 18,071 77,813 39,282 License and other revenue 626 303 1,015 625 Total revenue $ 40,086 $ 18,374 $ 78,828 $ 39,907 Cash, Cash Equivalents and Marketable Securities Cash and cash equivalents consist of cash on deposit with banks, money market instruments, and certificates of deposit with original maturities of three months or less at the date of purchase. Marketable securities consist of certificates of deposits that mature in greater than three months. Marketable securities are accounted for as "available-for-sale" with the carrying amounts reported in the balance sheets stated at cost, which approximates their fair market value, with unrealized gains and losses, if any, reported as a separate component of stockholders' equity and included in comprehensive loss. Restricted Cash Restricted cash represents amounts designated for uses other than current operations and was $1,646,000 and $758,000 as June 30, 2020 and December 31, 2019, respectively, which represented an amount held as security for the Company’s facility lease agreements. The following table shows a reconciliation of the Company's cash and cash equivalents in the Unaudited Condensed Consolidated Balance Sheet to cash, cash equivalents, and restricted cash in the Unaudited Condensed Consolidated Statement of Cash Flows as of June 30, 2020 and 2019 (in thousands): June 30, 2020 2019 Cash and cash equivalents $ 82,421 $ 23,733 Restricted cash 1,646 758 Total cash, cash equivalents, and restricted cash $ 84,067 $ 24,491 Receivables Accounts receivable consists of amounts due to the Company from the sale of products and services to customers. Accounts receivable is recognized at amortized cost and is recorded net of an allowance for credit losses. The Company views its accounts receivable as a single portfolio and considers period of delinquency, historical collection rates, and customer specific factors in determining its allowance for credit losses. The allowance for credit losses as of June 30, 2020 and 2019, comprised of the following (in thousands): Three Months Ended Six Months Ended 2020 2019 2020 2019 Beginning balance $ 405 $ 75 $ 376 $ 75 Provision for credit losses 737 46 766 46 Write off of uncollectible accounts (10) (14) (10) (14) Ending balance $ 1,132 $ 107 $ 1,132 $ 107 Product Warranties The Company generally offers a one-year warranty for instruments and a 60-day warranty for consumables sold to customers. Factors that affect the Company’s warranty reserves include the number of units sold, historical and anticipated rates of warranty repairs, and the cost per repair. The Company periodically assesses the adequacy of its warranty reserve and adjusts the amount as appropriate. Intangible Assets Intangible assets consist of licenses or sublicenses to technology covered by patents owned by third parties, and are amortized on a straight-line basis over the expected useful lives of these assets, which is generally ten Impairment of Long-Lived Assets The Company assesses the recoverability of long-lived assets, including intangible assets, by periodically evaluating the carrying value whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If impairment is indicated, the Company writes down the carrying value of the asset to its estimated fair value. This fair value is primarily determined based on estimated discounted cash flows. Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and include direct labor, materials, and manufacturing overhead. The Company periodically reviews inventory for evidence of slow-moving or obsolete parts, and writes inventory down to net realizable value, as needed. This write-down is based on management’s review of inventories on hand, compared to estimated future usage and sales, shelf-life assumptions, and assumptions about the likelihood of obsolescence. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Inventory impairment charges establish a new cost basis for inventory and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable. Property and Equipment, net Property, equipment and leasehold improvements are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which are identified below. Repair and maintenance costs are expensed as incurred. Machinery and laboratory equipment 3 - 5 years Instruments 4 - 5 years Office equipment 3 - 7 years Leasehold improvements Over the shorter of the remaining life of the lease or the useful economic life of the asset Leases The Company determines if an arrangement is a lease at inception. Operating leases are recorded in the consolidated balance sheets as noncurrent operating lease ROU assets and current and noncurrent operating lease liabilities. Finance leases are recorded in the consolidated balance sheets as other noncurrent assets and other current and noncurrent liabilities. ROU assets represent the Company’s right to use an underlying asset over the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease liabilities are recognized at the commencement date based on the present value of the Company’s lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of its lease payments. ROU assets are recognized at the commencement date based upon the initial measurement of the operating lease liability less any lease incentives received. The Company’s lease agreements can include both lease and non-lease components. The Company accounts for each lease component separately from the non-lease components within its lease agreements. Income Taxes Current income tax expense is the amount of income taxes expected to be payable for the current year. A deferred income tax liability or asset is established for the expected future tax consequences resulting from the differences in financial reporting and tax bases of assets and liabilities. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. A full valuation allowance has been recorded against the Company’s net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the future. The Company provides for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement standards prescribed by the authoritative guidance on income taxes. Amounts for uncertain tax positions are adjusted in periods when new information becomes available or when positions are effectively settled. The Company recognizes accrued interest related to uncertain tax positions as a component of income tax expense. A tax position that is more likely than not to be realized is measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement with the taxing authority that has full knowledge of all relevant information. Measurement of a tax position that meets the more likely than not threshold considers the amounts and probabilities of the outcomes that could be realized upon settlement using the facts, circumstances and information available at the reporting date.

Net Loss per Common Share (Note

Net Loss per Common Share (Notes)	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Net Loss per Common Share	Net Loss per Common ShareBasic net loss per share is calculated by dividing loss available to stockholders of the Company's common stock (the numerator) by the weighted average number of shares of the Company's common stock outstanding during the period (the denominator). Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted loss per share is calculated in a similar way to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the dilutive potential shares had been issued, unless the effect would be anti-dilutive. The calculations of diluted net loss per share for the three and six months ended June 30, 2020 and 2019 did not include the effects of the following stock options and other equity awards which were outstanding as of the end of each period because the inclusion of these securities would have been anti-dilutive (in thousands): Three Months Ended Six Months Ended 2020 2019 2020 2019 Options outstanding to purchase common stock 1,305 2,130 1,305 2,130 Other unvested equity awards 3,645 3,846 3,645 3,846 Total 4,950 5,976 4,950 5,976

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation Equity awards may be granted at the discretion of the Compensation Committee of the Board of Directors under the Company's equity plans, in connection with the hiring or retention of personnel and are subject to certain conditions. In May 2020, the Company’s stockholders approved the Company's 2020 Equity Incentive Plan, or the 2020 Plan. Prior to the adoption of the 2020 Plan, the Company granted equity awards under its 2010 Equity Incentive Plan, as amended, or the 2010 Plan, which expired in May 2020. The Company recognizes stock-based compensation expense related to stock options, restricted stock units, and market-based stock units granted to employees, directors, and non-employee advisors in exchange for services under the 2020 Plan and 2010 Plan, or the Equity Plans, and employee stock purchases under the Company's Amended and Restated 2013 Employee Stock Purchase Plan, or the ESPP. Employee participation in the Equity Plans is at the discretion of the Compensation Committee of the Board of Directors of the Company. Each equity award reduces the number of shares available for grant under the Plans. Stock-based compensation expense is recorded in cost of sales, sales and marketing, research and development, and general and administrative expense based on employees' respective function. During the six months ended June 30, 2020 and 2019, the Company recognized stock-based compensation expense of $8,048,000 and $5,711,000, respectively. The Company recognized stock-based compensation expense of $2,428,000 and $3,167,000, respectively, during the three months ended June 30, 2020 and 2019. Stock Options The fair value of stock options granted is derived from the Black-Scholes Option Pricing Model, which uses several judgment-based variables to calculate the expense. The inputs include the expected term of the stock option, the expected volatility, and other factors. • Expected Term. The expected term represents the period that the stock-based awards are expected to be outstanding and is determined by using the simplified method. • Expected Volatility . Expected volatility represents the estimated volatility in the Company’s stock price over the expected term of the stock option and is determined by review of the Company’s historical experience. • Expected Dividend . The Black-Scholes Option Pricing Model calls for a single expected dividend yield as an input. The Company has assumed no dividends as it has never paid dividends and has no current plans to do so. • Risk-Free Interest Rate. The risk-free interest rate used in the Black-Scholes Option Pricing Model is based on published U.S. Treasury rates in effect at the time of grant for periods corresponding with the expected term of the option. All stock options granted under the Plans are exercisable at a per share price equal to the closing quoted market price of a share of the Company’s common stock on the NASDAQ Global Market on the grant date and generally vest over a period of four ten The Company's stock option activity for the six months ended June 30, 2020 was as follows: Number of Weighted Average Exercise Price Outstanding at December 31, 2019 2,037,132 $ 9.53 Exercised (716,312) $ 5.63 Cancelled (15,444) $ 12.07 Outstanding at June 30, 2020 1,305,376 $ 11.64 Vested and expected to vest at June 30, 2020 1,305,376 $ 11.64 Exercisable at June 30, 2020 1,305,376 $ 11.64 There were 1,305,376 stock options exercisable and outstanding as of June 30, 2020, all of which were granted under the 2010 Plan and which had a remaining weighted average contractual term of 3.85 years and an aggregate intrinsic value of $4,007,000. The Company has recognized all compensation expense related to stock options granted under the 2010 Plan. The Company has not granted any stock options under the 2020 Plan. Restricted Stock Units Restricted stock units granted under the Plans generally vest over a period of between one four The Company’s restricted stock unit activity for the six months ended June 30, 2020 was as follows: Number of Weighted Unvested at December 31, 2019 2,669,499 $ 6.42 Granted 1,911,136 $ 4.24 Vested (1,181,901) $ 6.42 Cancelled (278,083) $ 6.14 Unvested at June 30, 2020 3,120,651 $ 5.11 As of June 30, 2020, there was $12,733,000 of unrecognized compensation cost related to unvested restricted stock units, which is expected to be recognized over a weighted average period of 2.32 years. The total grant date fair value of restricted stock units that vested during the six months ended June 30, 2020 and 2019 was $5,337,000 and $5,047,000, respectively. Market-Based Stock Units The Company granted market-based stock units in each of February 2020, 2019, and 2018, which may result in the recipient receiving shares of stock equal to 200% of the target number of units granted. The vesting and issuance of Company stock pursuant to market-based stock units depends on the Company's stock performance as compared to the NASDAQ Composite Index over the three The Company’s market-based stock unit activity for the six months ended June 30, 2020 was as follows: Number of Weighted Unvested at December 31, 2019 454,229 $ 9.40 Granted 321,250 $ 4.39 Vested (181,667) $ 9.52 Cancelled (69,378) $ 9.17 Unvested at June 30, 2020 524,434 $ 6.32 The fair value of these market-based stock units was estimated on the grant date using the Monte Carlo Simulation Valuation Model, which estimates the potential outcome of achieving the market conditions based on simulated future stock prices, with the following assumptions for the six months ended June 30, 2020 and 2019: Six Months Ended 2020 2019 Expected volatility 62 % 64 % Risk-free interest rate 1.16 % 2.50 % Expected dividend — % — % Weighted average fair value $ 4.39 $ 10.22 Employee Stock Purchase Plan The Company's stockholders originally approved the ESPP in May 2013. In May 2018, the Company's stockholders approved the amendment and restatement of the ESPP, which increased the shares authorized for issuance under the ESPP from 650,000 shares to 1,750,000 shares. The price at which stock is purchased under the ESPP is equal to 85% of the fair market value of the Company's common stock on the first or the last day of the offering period, whichever is lower. Generally, each offering under the ESPP will be for a period of six months as determined by the Company's Board of Directors; provided that no offering period may exceed 27 months. Employees may invest up to 10% of their qualifying gross compensation through payroll deductions. In no event may an employee purchase more than 1,500 shares of common stock during any six-month offering period. As of June 30, 2020, there were 627,886 shares of common stock available for issuance under the ESPP. The ESPP is a compensatory plan as defined by the authoritative guidance for stock compensation; therefore, stock-based compensation expense related to the ESPP has been recorded during each of the three and six months ended June 30, 2020 and 2019. Stock-Based Compensation Expense Recognition Stock-based compensation was recognized in the Unaudited Condensed Consolidated Statements of Comprehensive Loss as follows (in thousands): Three Months Ended Six Months Ended 2020 2019 2020 2019 Cost of revenue $ 310 $ 248 $ 549 $ 452 Sales and marketing 628 792 1,281 1,411 Research and development 553 449 973 872 General and administrative 937 1,678 5,245 2,976 Total stock-based compensation expense $ 2,428 $ 3,167 $ 8,048 $ 5,711 Stock-based compensation capitalized during the periods presented was not material and there was no unrecognized tax benefit related to stock-based compensation for either of the six months ended June 30, 2020 and 2019.

Stockholders' Equity (Notes)

Stockholders' Equity (Notes)	6 Months Ended
	Jun. 30, 2020
Stockholders' Equity Attributable to Parent [Abstract]
Stockholders' Equity	Stockholders' Equity On May 6, 2020, the Company entered into an Underwriting Agreement, or the Underwriting Agreement, with Cowen and Company, LLC and William Blair & Company, LLC acting as joint book-running managers and as representatives of the underwriters named therein, or collectively, the Underwriters, relating to the issuance and sale of 7,253,886 shares of the Company’s common stock, par value $0.0001 per share, or the Offering. Under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 1,088,082 shares of common stock. The Company closed the Offering on May 11, 2020 and sold 8,341,968 shares of common stock, including the full exercise of the Underwriters' option, at a public offering price of $9.65 per share before underwriting fees and discounts. The Company raised $80,500,000 in gross proceeds from the Offering and incurred $4,830,000 in underwriters’ discounts and $240,000 in professional services related to the Offering. On August 5, 2019, the Company entered into an Equity Distribution Agreement, or the Distribution Agreement, with Canaccord Genuity LLC, or Canaccord, pursuant to which the Company may offer and sell, from time to time, shares of the Company’s common stock having an aggregate offering price of up to $35,000,000. Under the Distribution Agreement, Canaccord may sell shares by any method deemed to be an “at-the-market” offering as defined in Rule 415 under the U.S. Securities Act of 1933, as amended, or any other method permitted by law, including in privately negotiated transactions. The Company is not obligated to sell any shares under the Distribution Agreement. Canaccord is entitled to a commission of 3% of the aggregate gross proceeds

Condensed Consolidated Financia

Condensed Consolidated Financial Statement Details (Notes)	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Consolidated Financial Statement Details	Condensed Consolidated Financial Statement Details The following tables show the Company's unaudited condensed consolidated financial statement details as of June 30, 2020 and December 31, 2019 (in thousands): Inventory June 30, 2020 December 31, 2019 Raw materials $ 6,761 $ 3,408 Work-in-process 4,548 3,776 Finished goods 3,618 4,117 Total inventories $ 14,927 $ 11,301 Property and Equipment, Net June 30, 2020 December 31, 2019 Property and equipment — at cost: Machinery and laboratory equipment $ 18,099 $ 16,551 Instruments 14,708 16,796 Office equipment 2,236 2,150 Leasehold improvements 11,993 11,896 Total property and equipment — at cost 47,036 47,393 Less: accumulated depreciation (27,616) (26,974) Property and equipment, net $ 19,420 $ 20,419

Intangible Assets, net (Notes)

Intangible Assets, net (Notes)	6 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible assets, net	. Intangible Assets, Net Intangible assets as of each of June 30, 2020 and December 31, 2019 comprised the following (in thousands): June 30, 2020 December 31, 2019 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Licensed intellectual property $ 4,750 $ (3,613) $ 1,137 $ 4,750 $ (3,318) $ 1,432 Intellectual property licenses have a weighted average remaining amortization period of 1.94 years as of June 30, 2020. Amortization expense for these licenses was $147,000 and $148,000 for the three months ended June 30, 2020 and 2019, respectively, and was $295,000 and $296,000 during the six months ended June 30, 2020 and 2019, respectively. Estimated future amortization expense for these licenses is as follows (in thousands): Fiscal Years Ending Future Amortization Expense Remaining in 2020 $ 296 2021 591 2022 250 Total $ 1,137

Loan Payable (Notes)

Loan Payable (Notes)	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Loan payable	Long-term debt As of June 30, 2020 and December 31, 2019, long-term debt consisted of the following (in thousands): June 30, 2020 December 31, 2019 Term Loan 70,000 70,000 Final fee obligation 4,865 4,165 Unamortized issuance costs (4,676) (5,020) Total debt, net 70,189 69,145 Current portion of long-term debt — — Long-term debt $ 70,189 $ 69,145 Term Loans On February 1, 2019, or the Effective Date, the Company entered into a Loan and Security Agreement, or the LSA, with Solar Capital Ltd. and certain other financial institutions, or, collectively, the Lenders. Pursuant to the LSA, the Lenders have provided the Company with a total of $70,000,000 in a series of term loans, or, collectively, the Term Loans, of which $50,000,000, was funded on the Effective Date and an additional $20,000,000, was funded in December 2019 upon the Company's achievement of a designated amount of product revenues on a trailing six-month basis. The Term Loans under the LSA accrue interest at a floating per annum rate in effect from time-to-time equal to (a) the greater of 2.51% or the one-month Intercontinental Exchange Benchmark Administration, Ltd. rate then in effect as of the applicable payment date, plus (b) 5.90% per annum. The Company is only required to make interest payments on amounts borrowed pursuant to the Term Loans from the applicable funding date until February 28, 2022, or the Interest Only Period. Following the Interest Only Period, monthly installments of principal and interest under the Term Loans will be due until the original principal amount and applicable interest is fully repaid by February 1, 2023. Under the LSA, the Company is required to comply with certain affirmative and negative covenants, including, without limitation, delivering reports and notices relating to the Company’s financial condition and certain regulatory events and intellectual property matters, as well as limiting the creation of liens, the incurrence of indebtedness, and the making of certain investments, dividends, payments and acquisitions, other than as specifically permitted by the New LSA. As of June 30, 2020, the Company was in compliance with all covenants under the LSA. The LSA also contains customary events of default (subject, in certain instances, to specified cure periods), including, but not limited to, the failure to make payments of interest or premium when due, the failure to comply with certain covenants and agreements specified in the LSA, and the occurrence of a material adverse change, certain regulatory events, or certain insolvency events. Upon the occurrence of an event of default, the Lenders may declare all outstanding principal and accrued but unpaid interest under the LSA immediately due and payable and may exercise the other rights and remedies as set forth in the LSA. Debt Issuance Costs As of June 30, 2020 and December 31, 2019, the Company had $4,676,000 and $5,020,000, respectively, of unamortized debt issuance discount, which is offset against borrowings in long-term and short-term debt. Amortization of debt issuance costs was $549,000 and $450,000 for the three months ended June 30, 2020 and 2019, respectively, and $1,145,000 and $816,000 for the six months ended June 30, 2020 and 2019, respectively. Amortization of debt issuance costs is included in interest expense in the Company's unaudited condensed consolidated statements of comprehensive loss for the periods presented. Letter of Credit The Company has provided an aggregate of $1,604,000 in letters of credit to the landlords of certain of its leased facilities and maintains $42,000 in required minimum account balances with the financial institutions issuing such letters of credit. As a result, the Company maintains $1,646,000 of restricted cash in connection with these lease agreements as of June 30, 2020.

Leases (Notes)

Leases (Notes)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Leases	Leases The Company has operating lease agreements for its office, manufacturing, warehousing and laboratory space. Rent and operating expenses charged under these arrangements was $468,000 and $483,000 for the three months ended June 30, 2020 and 2019, respectively, and $952,000 and $1,009,000 for the six months ended June 30, 2020 and 2019. The Company reported noncurrent operating lease ROU assets of $4,372,000 and $4,642,000, current operating lease liabilities of $1,870,000 and $1,842,000, and noncurrent operating lease liabilities of $5,217,000 and $5,796,000, respectively as of June 30, 2020 and December 31, 2019. The Company's operating lease liabilities were measured at a weighted average discount rate of 11.2% and have a weighted average remaining term of 4.49 years. As of June 30, 2020, the future minimum lease payments required under the Company's operating lease arrangements are as follows (in thousands): Fiscal Years Ending Future Minimum Lease Payments Remaining in 2020 $ 990 2021 2,015 2022 2,077 2023 1,939 2024 1,383 Thereafter 701 Total 9,105 Less: imputed interest (2,018) Total operating lease liabilities $ 7,087

Fair Value of Financial Instrum

Fair Value of Financial Instruments (Notes)	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Fair value of financial instruments	Fair Value of Financial Instruments The carrying amounts of financial instruments, such as cash equivalents, restricted cash, accounts receivable, and accounts payable approximate the related fair values due to the short-term maturities of these instruments. The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last is considered unobservable, to measure fair value: • Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The following table presents the financial instruments measured at fair value on a recurring basis and the valuation approach applied to each class of financial instruments as of June 30, 2020 and December 31, 2019 (in thousands): June 30, 2020 Quoted Prices Significant Significant Total Cash equivalents Money market funds $ 64,230 $ — $ — $ 64,230 Marketable securities Corporate notes and bonds — 21,822 — 21,822 U.S. government and agency securities — 1,500 — 1,500 Commercial paper — 27,052 — 27,052 Total $ 64,230 $ 50,374 $ — $ 114,604 December 31, 2019 Quoted Prices Significant Significant Total Cash equivalents Money market funds $ 19,647 $ — $ — $ 19,647 Marketable securities Corporate notes and bonds — 9,100 — 9,100 Total $ 19,647 $ 9,100 $ — $ 28,747

Marketable Securities (Notes)

Marketable Securities (Notes)	6 Months Ended
	Jun. 30, 2020
Investments, Debt and Equity Securities [Abstract]
Marketable securities	Marketable Securities The following table summarizes the Company’s marketable securities as of each of June 30, 2020 and December 31, 2019 (in thousands): June 30, 2020 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Corporate notes and bonds $ 21,791 $ 31 $ — $ 21,822 U.S. government and agency securities 1,500 — — 1,500 Commercial paper 27,051 1 — 27,052 Total $ 50,342 $ 32 $ — $ 50,374 December 31, 2019 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Corporate notes and bonds $ 9,099 $ 2 $ (1) $ 9,100 Total $ 9,099 $ 2 $ (1) $ 9,100

Income Taxes (Notes)

Income Taxes (Notes)	6 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates, and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter. As of June 30, 2020, the Company recorded a full valuation allowance against all of its net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the future. Due to the Company's losses, it only records a tax provision or benefit related to uncertain tax positions and related interest and minimum tax payments or refunds. The Company recorded income tax expense of $63,000 and $45,000 for the three months ended June 30, 2020 and 2019, respectively, and $78,000 and $61,000 for the six months ended June 30, 2020 and 2019, respectively. The Company is subject to taxation in the United States and in various state and foreign jurisdictions. The Company's federal and state tax returns since inception are subject to examination due to the carryover of net operating losses. The statute of limitations for the assessment and collection of income taxes related to other foreign tax returns varies by country. In the foreign countries where we have operations, these time periods generally range from three to five years after the year for which the tax return is due or the tax is assessed. In March 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, which includes modifications to the limitation on business interest expense and net operating loss provisions and provides a payment delay of employer payroll taxes during 2020 after the date of enactment. The Company is currently evaluating the impact of the CARES Act on its unaudited condensed consolidated financial statements.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On July 2, 2020, the Company entered into a Single Tenant Industrial Triple Net Lease, or the Lease, with Icon Owner Pool 1 West/Southwest, LLC, as landlord, or the Landlord. Pursuant to the Lease, the Company has leased an approximately 73,000 square foot facility in Carlsbad, California, or the Facility, which the Company may use for manufacturing, research and development, office, and/or distribution purposes. The original term of the Lease runs through June 30, 2031, provided that the Company may, subject to certain customary conditions as set forth in the Lease, extend the term of the Lease at fair market rental value for two additional five

Organization and Basis of Pre_2

Organization and Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes thereto. The Company’s significant estimates included in the preparation of the financial statements are related to accounts receivable, inventories, property and equipment, leases, intangible assets, employee-related compensation accruals, warranty liabilities, tax valuation accounts, and stock-based compensation. Actual results could differ from those estimates.
Segment Information	Segment Information The Company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales and support of instruments and molecular tests based on its proprietary eSensor ® detection technology. Substantially all of the Company’s operations and assets are in the United States.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or the FASB, or other standard setting bodies that the Company adopts as of the specified effective date. In February 2016, the FASB issued ASU 2016-02, Leases, which outlines a comprehensive lease accounting model and supersedes the prior lease guidance. The new guidance requires lessees to recognize lease liabilities and corresponding right-of-use, or ROU, assets for all leases with lease terms of greater than 12 months. The guidance also changes the definition of a lease and expands the disclosure requirements of lease arrangements. The new guidance must be adopted using the modified retrospective approach and is effective for annual periods beginning after December 15, 2018. The Company adopted the new standard in the first quarter of 2019 using the package of transition practical expedients. The Company recognized non-current ROU assets of $5,097,000 and current and non-current lease liabilities of $1,780,000 and $6,832,000, respectively, upon adoption. Deferred rent is now presented as an offset to the Company's non-current operating lease ROU assets. The new lease standard did not have a material impact on the Company's unaudited condensed consolidated statements of operations, cash flows, or stockholders' equity. In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments , which introduced a new methodology for recognizing credit losses on financial instruments. The new standard requires entities to measure financial instruments at their amortized cost basis, net of an allowance for credit losses. The allowance for credit losses must reflect an entity's current estimate of all expected credit losses. The new guidance also requires entities to present credit losses on debt securities accounted for under the available-for-sale method as an allowance rather than a write down. The Company adopted the new standard in the first quarter of 2020. The adoption of ASU 2016-13 did not have a material impact on the Company’s unaudited condensed consolidated financial statements for the three and six months ended June 30, 2020.
Revenue from Contract with Customer	Revenue The Company recognizes revenue from operations through the sale of products and other services. Product revenue comprises the sale of diagnostic tests and instruments. Other revenue primarily consists of freight revenue and revenue from extended service agreements. Revenue is recognized when control of products and services is transferred to the customer in an amount that reflects the consideration that the Company expects to receive from the customer in exchange for those products and services. This process involves identifying the contract with the customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control. Revenue from product sales is recognized generally upon shipment to the end customer, which is when control of the product is deemed to be transferred. Invoicing typically occurs upon shipment and the term between invoicing and when payment is due is not significant. Revenue from instrument services is recognized as the services are rendered, typically evenly over the contract term. Revenue is recorded net of discounts and sales taxes collected on behalf of governmental authorities. Employee sales commissions are recorded as sales and marketing expense when incurred or amortized over the estimated contract term when resulting from new contract acquisition efforts. The Company allocates contract price to each performance obligation in proportion to its stand-alone selling price. The stand-alone selling price is determined by the Company's best estimate of stand-alone selling price using average selling prices over a rolling 12-month period along with a specific assessment of any unique circumstances of the contract. For those products for which there is limited sales history, the Company makes price determinations based on similar product sales data. The following table represents disaggregated revenue by source (in thousands): Three Months Ended Six Months Ended 2020 2019 2020 2019 Revenue Source: ePlex product revenue $ 35,216 $ 11,935 $ 69,185 $ 27,466 XT-8 product revenue 4,244 6,136 8,628 11,816 Total product revenue 39,460 18,071 77,813 39,282 License and other revenue 626 303 1,015 625 Total revenue $ 40,086 $ 18,374 $ 78,828 $ 39,907
Cash, Cash Equivalents and Marketable Securities	Cash, Cash Equivalents and Marketable Securities Cash and cash equivalents consist of cash on deposit with banks, money market instruments, and certificates of deposit with original maturities of three months or less at the date of purchase. Marketable securities consist of certificates of deposits that mature in greater than three months. Marketable securities are accounted for as "available-for-sale" with the carrying amounts reported in the balance sheets stated at cost, which approximates their fair market value, with unrealized gains and losses, if any, reported as a separate component of stockholders' equity and included in comprehensive loss.
Receivables	Receivables Accounts receivable consists of amounts due to the Company from the sale of products and services to customers. Accounts receivable is recognized at amortized cost and is recorded net of an allowance for credit losses. The Company views its accounts receivable as a single portfolio and considers period of delinquency, historical collection rates, and customer specific factors in determining its allowance for credit losses. The allowance for credit losses as of June 30, 2020 and 2019, comprised of the following (in thousands): Three Months Ended Six Months Ended 2020 2019 2020 2019 Beginning balance $ 405 $ 75 $ 376 $ 75 Provision for credit losses 737 46 766 46 Write off of uncollectible accounts (10) (14) (10) (14) Ending balance $ 1,132 $ 107 $ 1,132 $ 107
Product Warranties	Product Warranties The Company generally offers a one-year warranty for instruments and a 60-day warranty for consumables sold to customers. Factors that affect the Company’s warranty reserves include the number of units sold, historical and anticipated rates of warranty repairs, and the cost per repair. The Company periodically assesses the adequacy of its warranty reserve and adjusts the amount as appropriate.
Intangible Assets	Intangible Assets Intangible assets consist of licenses or sublicenses to technology covered by patents owned by third parties, and are amortized on a straight-line basis over the expected useful lives of these assets, which is generally ten
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company assesses the recoverability of long-lived assets, including intangible assets, by periodically evaluating the carrying value whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If impairment is indicated, the Company writes down the carrying value of the asset to its estimated fair value. This fair value is primarily determined based on estimated discounted cash flows.
Inventories	Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and include direct labor, materials, and manufacturing overhead. The Company periodically reviews inventory for evidence of slow-moving or obsolete parts, and writes inventory down to net realizable value, as needed. This write-down is based on management’s review of inventories on hand, compared to estimated future usage and sales, shelf-life assumptions, and assumptions about the likelihood of obsolescence. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Inventory impairment charges establish a new cost basis for inventory and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable.
Property and Equipment, net	Property and Equipment, net Property, equipment and leasehold improvements are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which are identified below. Repair and maintenance costs are expensed as incurred. Machinery and laboratory equipment 3 - 5 years Instruments 4 - 5 years Office equipment 3 - 7 years Leasehold improvements Over the shorter of the remaining life of the lease or the useful economic life of the asset
Income Taxes	Income Taxes Current income tax expense is the amount of income taxes expected to be payable for the current year. A deferred income tax liability or asset is established for the expected future tax consequences resulting from the differences in financial reporting and tax bases of assets and liabilities. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. A full valuation allowance has been recorded against the Company’s net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the future. The Company provides for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement standards prescribed by the authoritative guidance on income taxes. Amounts for uncertain tax positions are adjusted in periods when new information becomes available or when positions are effectively settled. The Company recognizes accrued interest related to uncertain tax positions as a component of income tax expense. A tax position that is more likely than not to be realized is measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement with the taxing authority that has full knowledge of all relevant information. Measurement of a tax position that meets the more likely than not threshold considers the amounts and probabilities of the outcomes that could be realized upon settlement using the facts, circumstances and information available at the reporting date.

Organization and Basis of Pre_3

Organization and Basis of Presentation (Tables)	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Disaggregation of Revenue	The following table represents disaggregated revenue by source (in thousands): Three Months Ended Six Months Ended 2020 2019 2020 2019 Revenue Source: ePlex product revenue $ 35,216 $ 11,935 $ 69,185 $ 27,466 XT-8 product revenue 4,244 6,136 8,628 11,816 Total product revenue 39,460 18,071 77,813 39,282 License and other revenue 626 303 1,015 625 Total revenue $ 40,086 $ 18,374 $ 78,828 $ 39,907
Property, Plant and Equipment	Property, equipment and leasehold improvements are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which are identified below. Repair and maintenance costs are expensed as incurred. Machinery and laboratory equipment 3 - 5 years Instruments 4 - 5 years Office equipment 3 - 7 years Leasehold improvements Over the shorter of the remaining life of the lease or the useful economic life of the asset Property and Equipment, Net June 30, 2020 December 31, 2019 Property and equipment — at cost: Machinery and laboratory equipment $ 18,099 $ 16,551 Instruments 14,708 16,796 Office equipment 2,236 2,150 Leasehold improvements 11,993 11,896 Total property and equipment — at cost 47,036 47,393 Less: accumulated depreciation (27,616) (26,974) Property and equipment, net $ 19,420 $ 20,419

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Computations of diluted net loss per share	The calculations of diluted net loss per share for the three and six months ended June 30, 2020 and 2019 did not include the effects of the following stock options and other equity awards which were outstanding as of the end of each period because the inclusion of these securities would have been anti-dilutive (in thousands): Three Months Ended Six Months Ended 2020 2019 2020 2019 Options outstanding to purchase common stock 1,305 2,130 1,305 2,130 Other unvested equity awards 3,645 3,846 3,645 3,846 Total 4,950 5,976 4,950 5,976

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Schedule of share-based compensation, stock options, activity	six months ended June 30, 2020 was as follows: Number of Weighted Average Exercise Price Outstanding at December 31, 2019 2,037,132 $ 9.53 Exercised (716,312) $ 5.63 Cancelled (15,444) $ 12.07 Outstanding at June 30, 2020 1,305,376 $ 11.64 Vested and expected to vest at June 30, 2020 1,305,376 $ 11.64 Exercisable at June 30, 2020 1,305,376 $ 11.64
Schedule of share-based compensation, restricted stock units, activity	The Company’s restricted stock unit activity for the six months ended June 30, 2020 was as follows: Number of Weighted Unvested at December 31, 2019 2,669,499 $ 6.42 Granted 1,911,136 $ 4.24 Vested (1,181,901) $ 6.42 Cancelled (278,083) $ 6.14 Unvested at June 30, 2020 3,120,651 $ 5.11
Schedule of share-based compensation, market based stock units, activity	The Company’s market-based stock unit activity for the six months ended June 30, 2020 was as follows: Number of Weighted Unvested at December 31, 2019 454,229 $ 9.40 Granted 321,250 $ 4.39 Vested (181,667) $ 9.52 Cancelled (69,378) $ 9.17 Unvested at June 30, 2020 524,434 $ 6.32
Schedule of share-based compensation, market based stock units, valuation assumptions	The fair value of these market-based stock units was estimated on the grant date using the Monte Carlo Simulation Valuation Model, which estimates the potential outcome of achieving the market conditions based on simulated future stock prices, with the following assumptions for the six months ended June 30, 2020 and 2019: Six Months Ended 2020 2019 Expected volatility 62 % 64 % Risk-free interest rate 1.16 % 2.50 % Expected dividend — % — % Weighted average fair value $ 4.39 $ 10.22
Schedule of employee service share-based compensation, allocation of recognized period costs	Stock-based compensation was recognized in the Unaudited Condensed Consolidated Statements of Comprehensive Loss as follows (in thousands): Three Months Ended Six Months Ended 2020 2019 2020 2019 Cost of revenue $ 310 $ 248 $ 549 $ 452 Sales and marketing 628 792 1,281 1,411 Research and development 553 449 973 872 General and administrative 937 1,678 5,245 2,976 Total stock-based compensation expense $ 2,428 $ 3,167 $ 8,048 $ 5,711

Condensed Consolidated Financ_2

Condensed Consolidated Financial Statement Details (Tables)	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Inventories	Inventory June 30, 2020 December 31, 2019 Raw materials $ 6,761 $ 3,408 Work-in-process 4,548 3,776 Finished goods 3,618 4,117 Total inventories $ 14,927 $ 11,301
Property and equipment, net	Property, equipment and leasehold improvements are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which are identified below. Repair and maintenance costs are expensed as incurred. Machinery and laboratory equipment 3 - 5 years Instruments 4 - 5 years Office equipment 3 - 7 years Leasehold improvements Over the shorter of the remaining life of the lease or the useful economic life of the asset Property and Equipment, Net June 30, 2020 December 31, 2019 Property and equipment — at cost: Machinery and laboratory equipment $ 18,099 $ 16,551 Instruments 14,708 16,796 Office equipment 2,236 2,150 Leasehold improvements 11,993 11,896 Total property and equipment — at cost 47,036 47,393 Less: accumulated depreciation (27,616) (26,974) Property and equipment, net $ 19,420 $ 20,419

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	6 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of intangible assets	Intangible assets as of each of June 30, 2020 and December 31, 2019 comprised the following (in thousands): June 30, 2020 December 31, 2019 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Licensed intellectual property $ 4,750 $ (3,613) $ 1,137 $ 4,750 $ (3,318) $ 1,432
Summary of estimated future amortization expense	Estimated future amortization expense for these licenses is as follows (in thousands): Fiscal Years Ending Future Amortization Expense Remaining in 2020 $ 296 2021 591 2022 250 Total $ 1,137

Loan Payable (Tables)

Loan Payable (Tables)	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Schedule of long-term debt instruments	As of June 30, 2020 and December 31, 2019, long-term debt consisted of the following (in thousands): June 30, 2020 December 31, 2019 Term Loan 70,000 70,000 Final fee obligation 4,865 4,165 Unamortized issuance costs (4,676) (5,020) Total debt, net 70,189 69,145 Current portion of long-term debt — — Long-term debt $ 70,189 $ 69,145

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Schedule of future minimum lease payments	As of June 30, 2020, the future minimum lease payments required under the Company's operating lease arrangements are as follows (in thousands): Fiscal Years Ending Future Minimum Lease Payments Remaining in 2020 $ 990 2021 2,015 2022 2,077 2023 1,939 2024 1,383 Thereafter 701 Total 9,105 Less: imputed interest (2,018) Total operating lease liabilities $ 7,087

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Assets measured at fair value on a recurring basis	The following table presents the financial instruments measured at fair value on a recurring basis and the valuation approach applied to each class of financial instruments as of June 30, 2020 and December 31, 2019 (in thousands): June 30, 2020 Quoted Prices Significant Significant Total Cash equivalents Money market funds $ 64,230 $ — $ — $ 64,230 Marketable securities Corporate notes and bonds — 21,822 — 21,822 U.S. government and agency securities — 1,500 — 1,500 Commercial paper — 27,052 — 27,052 Total $ 64,230 $ 50,374 $ — $ 114,604 December 31, 2019 Quoted Prices Significant Significant Total Cash equivalents Money market funds $ 19,647 $ — $ — $ 19,647 Marketable securities Corporate notes and bonds — 9,100 — 9,100 Total $ 19,647 $ 9,100 $ — $ 28,747

Marketable Securities (Tables)

Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2020
Investments, Debt and Equity Securities [Abstract]
Marketable securities, gross unrealized gains/losses	June 30, 2020 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Corporate notes and bonds $ 21,791 $ 31 $ — $ 21,822 U.S. government and agency securities 1,500 — — 1,500 Commercial paper 27,051 1 — 27,052 Total $ 50,342 $ 32 $ — $ 50,374 December 31, 2019 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Corporate notes and bonds $ 9,099 $ 2 $ (1) $ 9,100 Total $ 9,099 $ 2 $ (1) $ 9,100

Organization and Basis of Pre_4

Organization and Basis of Presentation - Revenue disaggregation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation of Revenue
Revenue from Contract with Customer, Excluding Assessed Tax	$ 39,460	$ 18,071	$ 77,813	$ 39,282
License and other revenue	626	303	1,015	625
Total revenue	40,086	18,374	78,828	39,907
ePlex Revenue
Disaggregation of Revenue
Revenue from Contract with Customer, Excluding Assessed Tax	35,216	11,935	69,185	27,466
XT-8 Revenue
Disaggregation of Revenue
Revenue from Contract with Customer, Excluding Assessed Tax	$ 4,244	$ 6,136	$ 8,628	$ 11,816

Organization and Basis of Pre_5

Organization and Basis of Presentation - Property and equipment (Details)	6 Months Ended
	Jun. 30, 2020
Property and Equipment
Finite-Lived Intangible Asset, Useful Life	10 years
Machinery and laboratory equipment | Minimum
Property and Equipment
Property, Plant, and Equipment, Useful Life	3 years
Machinery and laboratory equipment | Maximum
Property and Equipment
Property, Plant, and Equipment, Useful Life	5 years
Instruments | Minimum
Property and Equipment
Property, Plant, and Equipment, Useful Life	4 years
Instruments | Maximum
Property and Equipment
Property, Plant, and Equipment, Useful Life	5 years
Office equipment | Minimum
Property and Equipment
Property, Plant, and Equipment, Useful Life	3 years
Office equipment | Maximum
Property and Equipment
Property, Plant, and Equipment, Useful Life	7 years
Leasehold improvements
Property and Equipment
Property, Plant and Equipment, Estimated Useful Lives	Over the shorter of the remaining life of the lease or the useful economic life of the asset

Organization and Basis of Pre_6

Organization and Basis of Presentation - Additional information (Details Textual)	3 Months Ended		6 Months Ended
	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)Segment	Jun. 30, 2019USD ($)	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (525,925,000)		$ (525,925,000)			$ (514,233,000)
Cash, cash equivalents, and marketable securities	132,795,000		132,795,000
Working Capital	138,267,000		$ 138,267,000
Sufficient capital to fund its operations			one
Number of Reportable Segments | Segment			1
Restricted cash	1,646,000	$ 758,000	$ 1,646,000	$ 758,000		758,000
Product Warranty Liability
Prior Period Reclassification Adjustment		149,000		309,000
Financing Receivable, Allowance for Credit Loss [Line Items]
Accounts Receivable, Allowance for Credit Loss	1,132,000	107,000	1,132,000	107,000	$ 405,000	$ 376,000	$ 75,000	$ 75,000
Accounts Receivable, Allowance for Credit Loss, Writeoff	(10,000)	(14,000)	(10,000)	(14,000)
Provision for bad debt	$ 737,000	$ 46,000	$ 766,000	$ 46,000
Instruments
Product Warranty Liability
Product warranty period			one-year
Reagents
Product Warranty Liability
Product warranty period			60-day

Organization and Basis of Pre_7

Organization and Basis of Presentation Recent Accounting Pronouncements (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019	Jan. 01, 2019
Text Block [Abstract]
Operating Lease, Liability, Current	$ 1,870,000	$ 1,842,000	$ 1,780,000
Operating Lease, Liability, Noncurrent	$ 5,217,000	$ 5,796,000	6,832,000
Operating Lease, Right Of Use Asset, Noncurrent			$ 5,097,000

Net Loss per Common Share - Bas

Net Loss per Common Share - Basic and diluted (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Computations of diluted net loss per share
Antidilutive securities excluded from calculation	4,950	5,976	4,950	5,976
Employee Stock Option
Computations of diluted net loss per share
Antidilutive securities excluded from calculation	1,305	2,130	1,305	2,130
Other unvested equity awards
Computations of diluted net loss per share
Antidilutive securities excluded from calculation	3,645	3,846	3,645	3,846

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock awards activity (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity award other than options, vested, shares	(181,667)
Equity award other than options, vested, weighted average grant date fair value	$ 9.52
2010 Equity Incentive Plan | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, outstanding at December 31, 2017, shares	2,037,132
Options, exercised, shares	(716,312)
Options, cancelled, shares	(15,444)
Options, outstanding at June 30, 2018, shares	1,305,376
Options, vested and expected to vest, shares	1,305,376
Options, exercisable, shares	1,305,376
Options, outstanding at December 31, 2017, weighted average exercise price	$ 11.64		$ 11.64	$ 9.53
Options, exercised, weighted average exercise price	5.63
Options, cancelled, weighted average exercise price	12.07
Options, outstanding at June 30, 2018, weighted average exercise price	11.64
Options, vested and expected to vest, weighted average exercise price	11.64
Options, exercisable, weighted average exercise price	$ 11.64
Options, outstanding, weighted average remaining contractual term	3 years 10 months 6 days
Options, outstanding, intrinsic value			$ 4,007
2010 Equity Incentive Plan | Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity award other than options, unvested at December 31, 2017, shares	2,669,499
Equity award other than options, granted, shares	1,911,136
Equity award other than options, vested, shares	(1,181,901)
Equity award other than options, cancelled, shares	(278,083)
Equity award other than options, unvested at June 30, 2018, shares	3,120,651
Equity award other than options, unvested, weighted average grant date fair value	$ 6.42
Equity award other than options, granted, weighted average grant date fair value	4.24
Equity award other than options, vested, weighted average grant date fair value	6.42
Equity award other than options, cancelled, weighted average grant date fair value	6.14
Equity award other than options, unvested, weighted average grant date fair value	$ 5.11
Equity award other than options, vested in period, fair value	$ 5,337	$ 5,047
Nonvested award, compensation cost not yet recognized			12,733
Nonvested award, compensation cost not yet recognized, weighted average period for recognition	2 years 3 months 25 days
2010 Equity Incentive Plan | Market-based share unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity award other than options, unvested at December 31, 2017, shares	454,229
Equity award other than options, granted, shares	321,250
Equity award other than options, cancelled, shares	(69,378)
Equity award other than options, unvested at June 30, 2018, shares	524,434
Equity award other than options, unvested, weighted average grant date fair value	$ 9.40
Equity award other than options, granted, weighted average grant date fair value	4.39	$ 10.22
Equity award other than options, cancelled, weighted average grant date fair value	9.17
Equity award other than options, unvested, weighted average grant date fair value	$ 6.32
Nonvested award, compensation cost not yet recognized			$ 1,444
Nonvested award, compensation cost not yet recognized, weighted average period for recognition	2 years

Stock-Based Compensation - Valu

Stock-Based Compensation - Valuation assumptions (Details) - 2010 Equity Incentive Plan - Market-based share unit - $ / shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value assumptions, expected volatility rate	62.00%	64.00%
Fair value assumptions, risk free interest rate	1.16%	2.50%
Fair value assumptions, expected dividend rate	0.00%	0.00%
Equity award other than options, granted, weighted average grant date fair value	$ 4.39	$ 10.22
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity award other than options, granted, weighted average grant date fair value	4.39
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity award other than options, granted, weighted average grant date fair value	$ 10.22

Stock-Based Compensation - Expe

Stock-Based Compensation - Expense recognition (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	$ 2,428,000	$ 3,167,000	$ 8,048,000	$ 5,711,000
Allocated share-based compensation expense, capitalized amount	0	0	0	0
Allocated share-based compensation expense, tax benefit	0	0	0	0
2010 Equity Incentive Plan | Cost of revenue
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	310,000	248,000	549,000	452,000
2010 Equity Incentive Plan | Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	628,000	792,000	1,281,000	1,411,000
2010 Equity Incentive Plan | Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	553,000	449,000	973,000	872,000
2010 Equity Incentive Plan | General and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	$ 937,000	$ 1,678,000	$ 5,245,000	$ 2,976,000

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional information (Details) - shares	6 Months Ended
	Jun. 30, 2020	May 22, 2013
2010 Equity Incentive Plan | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Award expiration period	10 years
2010 Equity Incentive Plan | Restricted Stock Units (RSUs) | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	1 year
2010 Equity Incentive Plan | Restricted Stock Units (RSUs) | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
2010 Equity Incentive Plan | Market-based share unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum MSU payout percentage	200.00%
Award vesting period	3 years
2013 Employee Stock Purchase Plan | Employee stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized		650,000
Number of shares available for grant	627,886
Discount from market price, offering date	85.00%
Maximum number of shares per employee	1,500
Maximum employee subscription rate	10.00%
2013 Employee Stock Purchase Plan | Employee stock | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Offering period	6 months
2013 Employee Stock Purchase Plan | Employee stock | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Offering period	27 months
2013 Employee Stock Purchase Plan Amended and Restated | Employee stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	1,750,000

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Type of Issuance Cost [Line Items]
Stock Issued During Period, Shares, New Issues (in shares)	363,120
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Shares Issued, Price Per Share (in dollars per share)	$ 9.65
Proceeds from Issuance or Sale of Equity	$ 80,500,000
Payments of Stock Issuance Costs	67,000
Maximum ATM Offering Amount	$ 35,000,000
Underwriters commission	3.00%
Weighted Average Price Per Share (in dollars per share)	$ 6.13
Gross Proceeds from Issuance of Common Stock	$ 2,227,000
Common Stock Available For Future Issuance	$ 19,714,000
Public Offering Shares Excluding Underwriters' Option [Member]
Type of Issuance Cost [Line Items]
Stock Issued During Period, Shares, New Issues (in shares)	7,253,886
Shares Attributable to Underwriters' Option [Member]
Type of Issuance Cost [Line Items]
Stock Issued During Period, Shares, New Issues (in shares)	1,088,082
Public Offering Shares, Including Underwriters' Option [Member]
Type of Issuance Cost [Line Items]
Stock Issued During Period, Shares, New Issues (in shares)	8,341,968
Issuance Costs Due To Underwriters [Member]
Type of Issuance Cost [Line Items]
Payments of Stock Issuance Costs	$ 4,830,000
Issuance Costs Due to Additional Parties
Type of Issuance Cost [Line Items]
Payments of Stock Issuance Costs	$ 240,000

Condensed Consolidated Financ_3

Condensed Consolidated Financial Statement Details - Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Summary of inventory on hand
Raw materials	$ 6,761	$ 3,408
Work-in-process	4,548	3,776
Finished goods	3,618	4,117
Total	$ 14,927	$ 11,301

Condensed Consolidated Financ_4

Condensed Consolidated Financial Statement Details - Property and equipment, net (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Property and Equipment
Property and equipment — at cost:	$ 47,036	$ 47,393
Less: accumulated depreciation	(27,616)	(26,974)
Property and equipment, net	19,420	20,419
Machinery and laboratory equipment
Property and Equipment
Property and equipment — at cost:	18,099	16,551
Instruments
Property and Equipment
Property and equipment — at cost:	14,708	16,796
Office equipment
Property and Equipment
Property and equipment — at cost:	2,236	2,150
Leasehold improvements
Property and Equipment
Property and equipment — at cost:	$ 11,993	$ 11,896

Intangible Assets, net - Compon

Intangible Assets, net - Components of gross and net intangible asset balances (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 147,000	$ 148,000	$ 295,000	$ 296,000
Finite-lived intangible assets
Net carrying amount	1,137,000		$ 1,137,000
Finite-lived intangible assets, remaining amortization period			1 year 11 months 8 days
Intellectual Property
Finite-lived intangible assets
Gross carrying amount	4,750,000		$ 4,750,000		$ 4,750,000
Accumulated amortization	(3,613,000)		(3,613,000)		(3,318,000)
Net carrying amount	$ 1,137,000		$ 1,137,000		$ 1,432,000

Intangible Assets, net - Future

Intangible Assets, net - Future amortization expense (Details) $ in Thousands	Jun. 30, 2020USD ($)
Summary of estimated future amortization expense
Remaining in 2020	$ 296
2020	591
2021	250
Net carrying amount	$ 1,137

Loan Payable - Term loans and l

Loan Payable - Term loans and line of credit (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 16, 2019	Feb. 01, 2019
Debt Instrument
Final fee obligation	$ 4,865,000		$ 4,865,000		$ 4,165,000
Unamortized debt issuance costs	(4,676,000)		(4,676,000)		(5,020,000)
Long-term debt, excluding current maturities	$ 70,189,000		70,189,000		69,145,000
Amortization of deferred debt issuance costs			1,145,000	$ 816,000
Debt instrument, maturity date	Feb. 1, 2023
Debt instrument, interest rate terms	(a) the greater of 2.51% or the one-month Intercontinental Exchange Benchmark Administration, Ltd. rate then in effect as of the applicable payment date, plus (b) 5.90% per annum
Term Loans, Debt Facility, Maximum Borrowing Capacity							$ 70,000,000
Letters of credit outstanding, amount	$ 1,604,000		1,604,000
Restricted cash	1,646,000	$ 758,000	1,646,000	758,000	758,000
Restricted Cash	42,000		42,000
Term Loans [Member]
Debt Instrument
Amortization of deferred debt issuance costs	549,000	$ 450,000	1,145,000	$ 816,000
Term Loan
Debt Instrument
Long-term debt	70,000,000		70,000,000		70,000,000
Total debt, net
Debt Instrument
Long-term debt	70,189,000		70,189,000		69,145,000
Long-term debt, current maturities	0		0		0
Long-term debt, excluding current maturities	$ 70,189,000		$ 70,189,000		$ 69,145,000
Tranche 1 Loan [Member]
Debt Instrument
Debt instrument, interest only period end	Feb. 28, 2022
Term Loans, Debt Facility, Maximum Borrowing Capacity							$ 50,000,000
Tranche 2 Loan [Member]
Debt Instrument
Term Loans, Debt Facility, Maximum Borrowing Capacity						$ 20,000,000

Leases - Future minimum lease p

Leases - Future minimum lease payments (Details) $ in Thousands	Jun. 30, 2020USD ($)
Schedule of future minimum lease payments
Remaining in 2020	$ 990
2019	2,015
2020	2,077
2021	1,939
2022	1,383
Thereafter	701
Total future minimum payments	9,105
Imputed interest, operating leases	(2,018)
Operating Lease, Liability	$ 7,087

Leases - Additional information

Leases - Additional information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Jan. 01, 2019
Lessee, Lease, Description [Line Items]
Rent and operating expenses	$ 468,000	$ 483,000	$ 952,000	$ 1,009,000
Operating Lease, Right Of Use Asset, Noncurrent						$ 5,097,000
Operating Lease, Liability, Current	1,870,000		1,870,000		$ 1,842,000	1,780,000
Operating Lease, Liability, Noncurrent	$ 5,217,000		$ 5,217,000		$ 5,796,000	$ 6,832,000
Operating Lease, Weighted Average Discount Rate, Percent	11.20%		11.20%
Operating Lease, Weighted Average Remaining Lease Term	4 years 5 months 26 days		4 years 5 months 26 days

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Fair value hierarchy (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Fair value, assets measured on a recurring basis
Marketable securities	$ 50,374	$ 9,100
Assets, Fair Value Disclosure	114,604	28,747
Level 1
Fair value, assets measured on a recurring basis
Assets, Fair Value Disclosure	64,230	19,647
Level 2
Fair value, assets measured on a recurring basis
Assets, Fair Value Disclosure	50,374	9,100
Level 3
Fair value, assets measured on a recurring basis
Assets, Fair Value Disclosure	0	0
U.S. government and agency securities
Fair value, assets measured on a recurring basis
Marketable securities	1,500
U.S. government and agency securities | Level 1
Fair value, assets measured on a recurring basis
Marketable securities	0
U.S. government and agency securities | Level 2
Fair value, assets measured on a recurring basis
Marketable securities	1,500
U.S. government and agency securities | Level 3
Fair value, assets measured on a recurring basis
Marketable securities	0
Corporate notes and bonds
Fair value, assets measured on a recurring basis
Marketable securities	21,822	9,100
Corporate notes and bonds | Level 1
Fair value, assets measured on a recurring basis
Marketable securities	0	0
Corporate notes and bonds | Level 2
Fair value, assets measured on a recurring basis
Marketable securities	21,822	9,100
Corporate notes and bonds | Level 3
Fair value, assets measured on a recurring basis
Marketable securities	0	0
Commercial paper
Fair value, assets measured on a recurring basis
Marketable securities	27,052
Commercial paper | Level 1
Fair value, assets measured on a recurring basis
Marketable securities	0
Commercial paper | Level 2
Fair value, assets measured on a recurring basis
Marketable securities	27,052
Commercial paper | Level 3
Fair value, assets measured on a recurring basis
Marketable securities	0
Money Market Funds [Member]
Fair value, assets measured on a recurring basis
Cash equivalents	64,230	19,647
Money Market Funds [Member] | Level 1
Fair value, assets measured on a recurring basis
Cash equivalents	64,230	19,647
Money Market Funds [Member] | Level 2
Fair value, assets measured on a recurring basis
Cash equivalents	0	0
Money Market Funds [Member] | Level 3
Fair value, assets measured on a recurring basis
Cash equivalents	$ 0	$ 0

Marketable Securities - Gross u

Marketable Securities - Gross unrealized gains/losses (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Marketable securities
Estimated fair value	$ 50,374	$ 9,100
Due in one year or less
Marketable securities
Amortized cost	(50,342)	(9,099)
Gross unrealized gains	32	2
Gross unrealized losses	0	(1)
Estimated fair value	50,374	9,100
Corporate notes and bonds
Marketable securities
Estimated fair value	21,822	9,100
Corporate notes and bonds | Due in one year or less
Marketable securities
Amortized cost	(21,791)	(9,099)
Gross unrealized gains	31	2
Gross unrealized losses	0	(1)
Estimated fair value	21,822	$ 9,100
U.S. government and agency securities
Marketable securities
Estimated fair value	1,500
U.S. government and agency securities | Due in one year or less
Marketable securities
Amortized cost	(1,500)
Gross unrealized gains	0
Gross unrealized losses	0
Estimated fair value	1,500
Commercial paper
Marketable securities
Estimated fair value	27,052
Commercial paper | Due in one year or less
Marketable securities
Amortized cost	(27,051)
Gross unrealized gains	1
Gross unrealized losses	0
Estimated fair value	$ 27,052

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ (63)	$ (45)	$ (78)	$ (61)

Subsequent Events (Details)

Subsequent Events (Details) ft² in Thousands	Jul. 02, 2020USD ($)ft²renewal_option	Jun. 30, 2020USD ($)
Subsequent Event [Line Items]
Letters of credit outstanding, amount		$ 1,604,000
Single Tenant Industrial Triple Net Lease [Member]
Subsequent Event [Line Items]
Letters of credit outstanding, amount		846,000
Payments for (Proceeds from) Tenant Allowance		$ 4,274,000
Subsequent Event | Single Tenant Industrial Triple Net Lease [Member]
Subsequent Event [Line Items]
Lessee, Operating Lease, Number of Renewal Options | renewal_option	2
Lessee, Operating Lease, Renewal Term	5 years
Lessee, Operating Lease, Term of Contract	12 months
Operating Lease, Area Of Leased Asset | ft²	73
Operating Lease, Annual Rent Increase	3.00%
Operating Leases, Rent Expense	$ 116,200